Vanderbilt Vaccine Center Archives
U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC
Apr. 6, 2021—The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
Novel way to neutralize Rift Valley Fever Virus
Apr. 1, 2021—The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.
Study shows new COVID target could improve vaccines
Apr. 1, 2021—Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.
Monoclonal antibody “cocktail” blocks COVID-19 variants: study
Mar. 4, 2021—A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.
Chikungunya antibody identified at VUMC moves forward
Mar. 4, 2021—Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
Exploiting viral vulnerabilities
Dec. 10, 2020—The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.
Vanderbilt University Medical Center’s Crowe receives 2020 “Golden Goose” Award for COVID-19 research
Dec. 1, 2020—James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award.
Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19
Jul. 15, 2020—Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
Research team isolates antibodies that may prevent rare polio-like illness in children linked to a respiratory infection
Jul. 3, 2020—Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.
Antibodies eye Pacific Island “fever”
May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.
Antibody finding raises hopes for Marburg, COVID-19 treatments
Apr. 30, 2020—Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody “cocktails” to counter viral infection.
Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments
Apr. 8, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
